Literature DB >> 20072146

Hypertension and paroxysmal atrial fibrillation: a novel predictive role of high sensitivity C-reactive protein in cardioversion and long-term recurrence.

I Rizos1, A G Rigopoulos, A S Kalogeropoulos, S Tsiodras, S Dragomanovits, E A Sakadakis, E Faviou, D T Kremastinos.   

Abstract

The role of inflammation in maintenance of paroxysmal atrial fibrillation (PAF) in patients with hypertension and no other heart disease has not been fully elucidated yet. We investigated the association of various inflammatory markers with cardioversion and recurrence of PAF in patients with hypertension. We studied 75 patients (44 male, mean age 67.9+/-9.9 years) with PAF (duration from onset of symptoms<24 h) secondary to hypertension. None had heart failure or any other ongoing inflammatory process. All patients received anticoagulation and intravenous amiodarone for cardioversion. High sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and tumour necrosis factor (TNF)-alpha were measured on admission and 48 h later. By 48 h from admission 61/75 patients (81.3%) regained sinus rhythm (cardioverted), whereas 14/75(18.7%) remained in AF (non-cardioverted). hsCRP, IL-6 and TNF-alpha serum levels on admission were similar between groups. hsCRP at 48 h was the most significant factor correlated with cardioversion outcome (OR: 0.06, 95% CI: 0.01-0.47, P=0.008). During a 1-year follow-up, AF recurred in 28/61(45.9%) patients. The strongest factor associated with AF recurrence was hsCRP at 48 h > or =2.27 mg l(-1) (hazard ratio: 6.2, 95% CI: 2.2-17.6, P=0.001). hsCRP at 48 h after admission correlates with cardioversion outcome and may predict long-term AF recurrence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20072146     DOI: 10.1038/jhh.2009.89

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

1.  NT-proBNP, but not ANP and C-reactive protein, is predictive of paroxysmal atrial fibrillation in patients undergoing pulmonary vein isolation.

Authors:  Jinqi Fan; Hua Cao; Li Su; Zhiyu Ling; Zengzhang Liu; Xianbin Lan; Yanping Xu; Weijie Chen; Yuehui Yin
Journal:  J Interv Card Electrophysiol       Date:  2011-09-21       Impact factor: 1.900

2.  Safety and efficacy outcomes of atrial fibrillation ablation in patients with rheumatoid arthritis.

Authors:  Ikram U Haq; Fahad K Lodhi; Abu Rmilah Anan; Hossam Alzu'bi; Kolade M Agboola; Hon-Chi Lee; Samuel J Asirvatham; Abhishek J Deshmukh; Christopher V DeSimone
Journal:  Heart Rhythm O2       Date:  2022-03-15

3.  Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation.

Authors:  Andreas S Kalogeropoulos; Sotirios Tsiodras; Angelos G Rigopoulos; Eleftherios A Sakadakis; Andreas Triantafyllis; Dimitrios Th Kremastinos; Ioannis Rizos
Journal:  BMC Cardiovasc Disord       Date:  2011-12-28       Impact factor: 2.298

4.  Predictors of atrial fibrillation recurrence after cryoballoon ablation.

Authors:  Tolga Aksu; Erkan Baysal; Tümer Erdem Guler; Sukriye Ebru Golcuk; İsmail Erden; Kazim Serhan Ozcan
Journal:  J Blood Med       Date:  2015-06-29

5.  New-Onset Atrial Fibrillation in Acute Myocardial Infarction Is a Different Phenomenon than Other Pre-Existing Types of That Arrhythmia.

Authors:  Monika Raczkowska-Golanko; Krzysztof Młodziński; Grzegorz Raczak; Marcin Gruchała; Ludmiła Daniłowicz-Szymanowicz
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

Review 6.  Value of high-sensitivity C-reactive protein assays in predicting atrial fibrillation recurrence: a systematic review and meta-analysis.

Authors:  Chia-Hung Yo; Si-Huei Lee; Shy-Shin Chang; Matthew Chien-Hung Lee; Chien-Chang Lee
Journal:  BMJ Open       Date:  2014-02-20       Impact factor: 2.692

Review 7.  Atrial Fibrillation: The Science behind Its Defiance.

Authors:  Maureen E Czick; Christine L Shapter; David I Silverman
Journal:  Aging Dis       Date:  2016-10-01       Impact factor: 6.745

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.